15:34:13 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-04-30 Ordinarie utdelning GENT 0.00 NOK
2024-04-30 Kvartalsrapport 2024-Q1
2024-04-29 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning GENT 0.00 NOK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss, Norge.
2023-05-05 07:30:00
Moss, 5 May 2023

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the first quarter of 2023.

Highlights
Record sales of MNOK 31.4, up 53% from 1Q22, with organic growth of 40%. All
products and geographic areas demonstrated positive sales development in 1Q23
compared to 1Q22.

Demand for Cystatin C in China has stabilised after the end of the
corona-related lock-down.

New diagnostic guidelines in the US and co-marketing efforts with commercial
partner Beckman Coulter resulted in new customers for Cystatin C in the US and
in Europe.

Further results from scientific studies confirmed the clinical relevance and
benefits of GCAL for the early detection and severity assessment of infections.

EBITDA was MNOK -0.5 in 1Q23 versus MNOK -4.2 in 1Q22. R&D costs were MNOK 6.6
in the quarter.

"The global demand for diagnostics continues to be robust even in uncertain
times, driven by a growing and ageing population. We are continuously innovating
diagnostic efficiency to get faster patient results and increase clinical
efficiency, and the market response is a clear signal that we are adding real
value to our customers. I'm particularly pleased that we deliver growth across
all products, all geographies and all sales channels," says CEO Hilja Ibert of
Gentian Diagnostics.

Gentian converts existing biomarkers to the most efficient automated,
high-throughput analysers, which contributes to saving costs and protecting
life. The company's go-to-market strategy has proven successful with annual
sales growth averaging 28% over the past four years. Gentian's five
revenue-generating products are sold in Europe, the US and Asia. In addition,
the company invests in product development with the current pipeline comprising
NT-proBNP in product development and further two undisclosed projects in the
proof-of-concept phase.

Webcast
Gentian's CEO Hilja Ibert and CFO Njaal Kind will present the results today at
09:00 am CEST, followed by a Q&A session. Join the webcast and submit questions
via the following link:

https://register.gotowebinar.com/register/1605516105712686432

The webcast will be available on the company's IR website after the
presentation.


IR contact:

Njaal Kind, CFO and COO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian
Diagnostics ASA, on 5 May 2023 at 07:30 CET.